BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|July 1, 2007
- Volume 0 0
Update on Investigational Alzheimer's Drug
Author(s)Susan Farley
Advertisement
Voyager Pharmaceutical Corp recently informed its shareholders of preliminary results from a trial of an investigational drug to treat Alzheimer's disease (AD). The researchers studying the drug, Memryte, observed positive effects among women but not among men.
The findings have prompted Voyager to focus on developing the drug to treat AD specifically for women.
Articles in this issue
over 19 years ago
pharmacy TECHNOLOGY newsover 19 years ago
pharmacy TECHNOLOGY productsover 19 years ago
health-systems PRODUCT newsover 19 years ago
generic times product newsover 19 years ago
can you READ these Rxs?over 19 years ago
A closer look at new FDA actionsover 19 years ago
can you READ these Rxs?over 19 years ago
compounding HOTLINEover 19 years ago
Is There Science in Quality?over 19 years ago
Vaccines: Are You Protected?Advertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
What the 2025-2030 Dietary Guidelines Mean for Heart Health
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
5